Key facts
- This page summarizes John F. Neylan's Form 4 filing for Angion Biomedica Corp. (ELTX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 04 Mar 2022, 15:21.
John F. Neylan - 02 Mar 2022 Form 4 Insider Report for Angion Biomedica Corp. (ELTX)
- Reporting relationship
- Executive Vice President, Chief Medical Officer and Head of Research
- Issuer ticker
- ELTX
- Reported as of
- 02 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2022, 15:21:53 UTC
- Prior SEC filing
- 21 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer J. Rhodes, as attorney-in fact for John F. Neylan
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
John F. Neylan filed Form 4 for Angion Biomedica Corp. (ELTX) on 04 Mar 2022.
Change
- Previous filing in this sequence was filed on 21 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +175,000
- Change %
- Price
- $0.000000
- Shares after
- 175,000
- Date
- 02 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 175,000
- Exercise price
- $1.99
- Footnotes
- F1
ELTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- +57%
- Price
- $0.000000
- Shares after
- 275,000
- Date
- 02 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $1.99
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The total number of options vest in forty-eight (48) successive and equal monthly installments as measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Footnote F2
The total number of options vest in equal parts on July 31, 2022 and December 31, 2022, such that 100% of the options will be fully vested and exercisable on December 31, 2022.
SEC remarks
Executive Vice President, Chief Medical Officer and Head of Research